Protocol Ledger

NCT07424404 · Phase III · RECRUITING

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

Interventional Phase III clinical trial protocol NCT07424404 sponsored by Bristol Myers Squibb in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-07 Enrollment: 400 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07424404
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)400 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07424404
Protocol FieldVerified Registry Value
NCT IdentifierNCT07424404
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment400 participants (ESTIMATED)
Registered Start Date2026-04-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI